NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.1325
0.00 (0.00%)
Sep 11, 2025, 3:53 PM EDT
NKGen Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
63
Market Cap
9.90M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 77.00K | -349.00K | -81.92% |
Dec 31, 2021 | 426.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNKGen Biotech News
- 4 days ago - NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - GlobeNewsWire
- 5 weeks ago - NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - GlobeNewsWire
- 6 weeks ago - NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025 - GlobeNewsWire
- 7 weeks ago - NKGen Biotech to Present at the Alzheimer's Association International Conference 2025 - GlobeNewsWire
- 2 months ago - NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewsWire
- 2 months ago - NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy - GlobeNewsWire
- 2 months ago - NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida - GlobeNewsWire